Glomerular hyperfiltration

Glomerular hyperfiltration is a physiological condition in which the glomeruli in the kidney filter blood at abnormally high rates, often defined as a GFR two standard deviations above the population mean for age and sex[3][6]. It can be a transient physiological response (e.g., after high-protein meals or during pregnancy) but is most concerning as an early hallmark of kidney stress and injury, particularly in diabetes, obesity, or following compensatory adaptation to nephron loss[1][3][5]. Pathophysiologically, it involves increased glomerular capillary pressure, often due to altered afferent/efferent arteriolar tone, hypertrophy of glomeruli, and dysregulated tubuloglomerular feedback. Glomerular hyperfiltration is associated with later development of albuminuria, accelerated kidney function decline, and increased cardiovascular events and mortality[3][8][9]. Its reversal or prevention (e.g., by RAAS inhibitors, SGLT2 inhibitors, or lifestyle weight loss) is a therapeutic cornerstone in the management of progressive kidney disease, but glomerular hyperfiltration itself is a *pathophysiologic process*, not a discrete molecular drug target[3][8]. Key points: - Glomerular hyperfiltration is not a molecule, receptor, or traditional therapeutic target. - It is a renal functional state indicative of increased risk, particularly in the context of diabetes, obesity, and kidney injury. - Therapies are directed at modifying the underlying physiology, not at “targeting” a protein by this name.

Other names

Renal hyperfiltration

Reduce intraglomerular (capillary) pressure by modulating afferent and/or efferent arteriolar tone; Restore tubuloglomerular feedback (e.g., SGLT2 inhibition increases sodium delivery to the macula densa, leading to afferent arteriolar constriction and reduced GFR); Block maladaptive neurohormonal pathways (e.g., RAAS inhibition dilates efferent arteriole); Decrease proximal tubular sodium reabsorption, reducing feedback-mediated hyperfiltration